biologic

Lemtrada

alemtuzumab

Loss of exclusivityNovember 2026projected — 12-year biologic exclusivity estimate
CompanyGenzyme Corporation

Drug detail

Brand nameLemtrada
Active ingredientalemtuzumab
Strength12MG/1.2ML (10MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2014
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Lemtrada patent cliff — loss of exclusivity November 2026 | CliffBio